{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-010666","form_type":"8-K","ticker":"ZOMDF","cik":"0001684144","company_name":"Zomedica Corp.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.106910+00:00","generated_at":"2026-05-31T09:22:17.171965+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"medium","headline":"Zomedica reports record FY2023 revenue $25.2M (+33% YoY); net loss $34.5M; guides FY2024 $31-35M","bullets":["Q4 2023 revenue $7.3M (+19% YoY); FY2023 revenue $25.2M (+33% YoY), driven by Diagnostics (+252%) and Therapeutic Devices (+28%).","Gross margin 69% for FY2023; consumable revenue $16.4M (+41% YoY), 65% of total revenue.","Net loss $34.5M ($0.035/share) vs $17.0M in FY2022; Adjusted Non-GAAP EBITDA loss $12.8M.","Cash and securities $100.5M at Dec 31, 2023; reiterated FY2024 revenue guidance $31-35M.","Acquisitions of SMP (VetGuardian) and Qorvo Biotechnologies in 2023; launched TRUVIEW and new assays."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-010666","json":"https://secwatch.observer/filing/0001654954-24-010666.json","markdown":"https://secwatch.observer/filing/0001654954-24-010666.md","text":"https://secwatch.observer/filing/0001654954-24-010666.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1684144/000165495424010666/0001654954-24-010666-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1684144/000165495424010666/zom_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:22:17.171965+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}